Skip to main content
. 2017 Oct 26;7:14111. doi: 10.1038/s41598-017-13927-7

Table 3.

Association of different phospholipid species and total triglycerides with OC usage and cortisol.

Compound OC usage cortisol p-value for mediationd
Model 1a Model 2b Model 3a
Mis., % b(95%-CI) for OC usage pc b(95%-CI) for OC usage pc b(95%-CI) for cortisol pc
Triglycerides 1.7 0.37(0.18; 0.57) 0.0001 0.27(0.06; 0.48) 0.0129 0.22(0.11; 0.34) 0.0001 0.020
1-linoleoylglycerophosphocholine (18:2n6) 0.4 −0.23(−0.37; −0.10) 0.0009 −0.17(−0.33; 0.00) 0.0548 −0.14(−0.24; −0.04) 0.006 0.122
1-palmitoylglycerophosphate 8.3 0.36(0.17; 0.56) 0.0002 0.16(−0.06; 0.38) 0.1425 0.28(0.16; 0.39) 2.26e-06 0.001
2-linoleoylglycerophosphocholine 0.4 −0.24(−0.39; −0.10) 0.0011 −0.14(−0.32; 0.05) 0.1539 −0.17(−0.27; −0.08) 0.0004 0.029
1-palmitoylglycerophosphoinositol 17.0 0.44(0.30; 0.59) 5.99e-09 0.29(0.08; 0.49) 0.0061 0.29(0.20; 0.38) 1.30e-09 0.007
1-palmitoylglycerophosphoethanolamine 0.4 0.32(0.19; 0.44) 1.08e-06 0.15(0.00; 0.29) 0.0486 0.24(0.15; 0.33) 1.62e-07 0.004
2-palmitoylglycerophosphoethanolamine 20.9 0.30(0.14; 0.46) 0.0002 0.13(−0.07; 0.33) 0.1969 0.24(0.13; 0.33) 1.12e-05 0.001
1-oleoylglycerophosphoinositol 9.6 0.36(0.18; 0.54) 0.0001 0.24(0.02; 0.46) 0.0350 0.23(0.11; 0.35) 0.0002 0.045
1-docosapentaenoylglycerophosphocholine (22:5n3) 1.3 −0.41(−0.60; −0.22) 3.88e-05 −0.28(−0.51; −0.05) 0.0170 −0.25(−0.38; −0.12) 0.0001 0.033
1-docosahexaenoylglycerophosphoethanolamine 0.4 0.24(0.12; 0.35) 5.05e-05 0.12(−0.02; 0.26) 0.0812 0.17(0.10; 0.25) 7.65e-06 0.005

aModel 1: adjusted for age, waist circumference, blood cell counts, fasting time and time of blood sampling. bModel 2: adjusted for age, waist circumference, blood cell counts, fasting time, time of blood sampling and cortisol. cUncorrected p-values; Bonferroni threshold = 0.0012 (correcting for 41 test). dBootstrap derived p-value using 1000 replications for the significance of the indirect effect (difference between regression weights of OC intake between model 1 and model 2).